Table 3.

Overview of severe thrombotic complications despite prophylaxis with enoxaparin and AT III

Patients with deep vein thrombosis	Location of thrombosis	Risk factors (hypertriglyceridemia, hyperleukocytosis, sepsis, adipositas, genetic)	Gender	Age at thrombosis [years]	Treatment received for thrombosis	Interruption of L-asparaginase during further therapy	Recurrence of deep vein thrombosis at a later date
#1	V. axillaris/sub-clavia sinistra	no	male	7.35	Unfractionated heparin via perfusor for 5 days, then switch to enoxaparin twice daily in therapeutic dose for 12 days, after that once daily	no	no
#2	Sinus vein	no	female	3.27	Unfractionated heparin via perfusor for 5 days, then switch to enoxaparin twice daily in therapeutic dose until recanalization of sagittal sinus after 8 weeks	no	no
#3	Vv. iliacae internae	Massive hypertriglyceridemia, adipositas	male	12.03	Unfractionated heparin via perfusor (dose 20 IE/kg/h) for 14 days, then switch to enoxaparin twice daily in therapeutic dose	no	no
#4	V. fibularis sinistra	Heterozygous mutation FactorII (G20210A), homozygous MTHFR mutation (C677T)	male	17.90	Enoxaparin twice daily in therapeutic dose during whole intensive therapy, once daily during maintenance	no	no
#5	Vv. iliacae externae	no	male	5.11	Enoxaparin twice daily in therapeutic dose	no	no